SHARE

March 02, 2023

PTO Seeks Comments on Role of Artificial Intelligence in Inventorship

You've Reached Your
Free Article Limit This Month
Register for free to get unlimited access to all Law.com OnPractice content.
Register Now

The US Patent & Trademark Office (PTO) published a Request for Comments Regarding Artificial Intelligence and Inventorship seeking input from stakeholders on inventorship issues that may arise as artificial intelligence (AI) and emerging technologies play a greater role in the innovation process. The deadline to submit comments is May 15, 2023.

As background, the PTO held its inaugural AI and Emerging Technologies Partnership meeting, during which panelists discussed AI's increasing role in innovation, in June 2022. Although there appeared to be consensus that AI cannot "conceive" of inventions, some panelists contended that AI is merely a tool like any other tool used in the inventive process, while others pointed to situations in which AI systems can output patentable inventions or contribute at the level of a joint inventor. While the PTO has been exploring the contours of inventorship law with respect to AI-generated inventions, in August 2022, the US Court of Appeals for the Federal Circuit issued its decision in Thaler v. Vidal, finding that inventorship is limited to natural persons. The Court explained, however, that it was not confronted with "the question of whether inventions made by human beings with the assistance of AI are eligible for patent protection."

Recognizing the uncertainty surrounding the role of AI inventorship in the wake of the Thaler decision, the PTO seeks public comment on several questions, including the following:

1. How is AI, including machine learning, currently being used in the invention creation process?

2. How does the use of an AI system in the invention creation process differ from the use of other technical tools?

3. If an AI system contributes to an invention at the same level as a human who would be considered a joint inventor, is the invention patentable under current patent laws?

4. Do inventions in which an AI system contributed at the same level as a joint inventor raise any significant ownership issues?

5. Is there a need for the PTO to expand its current guidance on inventorship to address situations in which AI significantly contributes to an invention? How should the significance of a contribution be assessed?

6. Should the PTO require applicants to provide an explanation of contributions AI systems made to inventions claimed in patent applications? If so, how should that be implemented, and what level of contributions should be disclosed? Should contributions to inventions made by AI systems be treated differently from contributions made by other (e., non-AI) computer systems?

7. What additional steps, if any, should the PTO take to further incentivize AI-enabled innovation (e.g., innovation in which machine learning or other computational techniques play a significant role in the invention creation process)?

8. What statutory changes, if any, should be considered as to US inventorship law, and what consequences do you foresee for those statutory changes?

ALM expressly disclaims any express or implied warranty regarding the OnPractice Content, including any implied warranty that the OnPractice Content is accurate, has been corrected or is otherwise free from errors.

More From McDermott Will & Emery

Welcome Chris Salmen

By Christopher Salmen McDermott Will & Emery May 24 , 2023

Chris Salmen joined McDermott+Consulting earlier this month as a senior director, bringing his unique blend of medical device, diagnostic and digital health experience to advise clients on their go-to-market strategy.

Debt Limit Deadlock Continues

By Debra Curtis McDermott Will & Emery May 22 , 2023

Debbie Curtis and Rodney Whitlock discuss what the debt limit deadlock means for healthcare stakeholders as the June 1 deadline draws closer.

McDermottPlus Check-Up: May 19, 2023

By Debra Curtis McDermott Will & Emery May 19 , 2023

The House and Senate were both in session this week, with significant healthcare activity at the committee level.

More From Artificial Intelligence

Weeded Out: Mark for Drug Paraphernalia Described as "Essential Oil Dispenser" Refused Registration

By Tessa Kroll McDermott Will & Emery May 18 , 2023

Addressing the registrability of marks for cannabis-related products, the Trademark Trial & Appeal Board upheld an Examiner’s refusal to register marks for an “essential oil dispenser” based on extrinsic evidence that the dispenser was primarily used with cannabis extract.

Pending Appeal Does Not Divest Board of Statutory Authority to Institute IPRs

By Amol Parikh McDermott Will & Emery May 18 , 2023

In a case involving sua sponte review, the Director of the US Patent & Trademark Office (PTO) vacated an inter partes review (IPR) decision denying institution, found that the Patent Trial & Appeal Board had statutory authority to institute IPR review of a claim that had been previously found invalid by a district court under 35 U.S.C. § 101 (but under appeal), and remanded the proceeding for the Board to consider whether discretionary denial was appropriate.

McDermottPlus Check-Up: May 12, 2023

By Debra Curtis McDermott Will & Emery May 12 , 2023

The House and Senate were both in session this week.

Featured Stories
Closeclose
Search
Menu

Working...